Saxenda (liraglutide) is a GLP-1 receptor agonist licensed in the UK for weight management in adults with obesity or overweight with weight-related comorbidities
If you like these stacks, and would like to discover more stacks like these, then check out our free stack guides
Written by: Anjali Dharra
As per the Leerink analysts, Lilly has indicated that it could potentially co-formulate eloralintide with tirzepatide or its other experimental obesity drug retatrutide, though the pharma is administering the drugs separately in current trials
During this initial appointment, our clinical team will evaluate your physical and metabolic vitals, including: Cardiovascular & Blood Volume Baseline: Reviewing active blood pressure, heart rate, and metabolic vitals to ensure total safety before prescribing advanced peptide or GLP-1 therapies
Seeing improvements in certain markers can be really encouraging and reinforce that the treatment is working well for you